Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

Gemtuzumab ozogamicin (GO, Mylotarg(®)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Mol Sci
Egile Nagusiak: Fenwarth, Laurène, Fournier, Elise, Cheok, Meyling, Boyer, Thomas, Gonzales, Fanny, Castaigne, Sylvie, Boissel, Nicolas, Lambert, Juliette, Dombret, Hervé, Preudhomme, Claude, Duployez, Nicolas
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2020
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7460695/
https://ncbi.nlm.nih.gov/pubmed/32781546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21165626
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak